.jpg)
.jpg)
.jpg)
China Pharmaceutical R&D Summit
创药到前临床开发、及合作的议程
日程表(PDF) (95K PDF)
2011年4月11日 (一) | 2011年4月12日 (二) | 2011年4月13日 (三)
8:00
Conference Registration Begins
8:30
Chairperson's Opening Remarks
Seymour Mong, Ph.D., Independent Consultant
Seymour Mong, Ph.D., Independent Consultant
特选简报
8:40
Challenges and Opportunities for Drug Innovation in China
The challenges lie in insufficient IPR protection, reviewing and approving process for clinical research for new drugs, drug administration and licensing system, clinical research resources, compliance of GCP and market access which is not encouraging drug innovation. Recently, importance of drug innovation has been recognized and reflected in the 12th 5 year plan and some measures have been initiated by the government and industrial groups, but lots of effort are still needed to create a more R&D friendly environment for drug innovation in China.
Joseph (YungChing) Cho, President & CEO, Astellas Pharma China Inc.; Vice Chairman, R&D Pharmaceutical Association in China (RDPAC)
The challenges lie in insufficient IPR protection, reviewing and approving process for clinical research for new drugs, drug administration and licensing system, clinical research resources, compliance of GCP and market access which is not encouraging drug innovation. Recently, importance of drug innovation has been recognized and reflected in the 12th 5 year plan and some measures have been initiated by the government and industrial groups, but lots of effort are still needed to create a more R&D friendly environment for drug innovation in China.
Joseph (YungChing) Cho, President & CEO, Astellas Pharma China Inc.; Vice Chairman, R&D Pharmaceutical Association in China (RDPAC)
中国的新药研究开发之MNC策略
9:10
Bridging Research and Development Fast to POC
This presentation will elaborate ways to improve probability of success for compounds and to decresase compound development time. With innovative technology advancement in target delivery and formulation development, many of the previously non-developable compounds could be developed for market uses. In many ways, this could revolutionize the drug development landscape in future. With the right regulation in place from SFDA, China could play a significant role in this exciting development period.
Nick (Yafei) Zhang, Ph.D., Head of CPP China, China Novartis Institutes for BioMedical Research
This presentation will elaborate ways to improve probability of success for compounds and to decresase compound development time. With innovative technology advancement in target delivery and formulation development, many of the previously non-developable compounds could be developed for market uses. In many ways, this could revolutionize the drug development landscape in future. With the right regulation in place from SFDA, China could play a significant role in this exciting development period.
Nick (Yafei) Zhang, Ph.D., Head of CPP China, China Novartis Institutes for BioMedical Research
9:40
Creating Value through Partnerships
At this time of unprecedented opportunities, creative solutions and continued research collaborations are required. The new sanofi-aventis R&D values networks and focuses on partnership and collaboration. Aiming to incorporate innovation into the main fabric of R&D, we set up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.
Binhui (Ben) Ni, Ph.D., Head of Scouting and Partnership, China, sanofi-aventis
At this time of unprecedented opportunities, creative solutions and continued research collaborations are required. The new sanofi-aventis R&D values networks and focuses on partnership and collaboration. Aiming to incorporate innovation into the main fabric of R&D, we set up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.
Binhui (Ben) Ni, Ph.D., Head of Scouting and Partnership, China, sanofi-aventis
10:10
Networking Refreshment Break and Opening of Exhibit & Poster Hall
国内企业的NCE创药及开发
10:45
Best-in-Class in China: Generic New Drugs
Generic new drugs are being pushed to develop multiple Best-in-Class drugs to cover all patient population of all income levels in China and around the globe. The general approach as well as Hec Pharma's effort toward generic new drugs will be discussed.
PengCho Tang, Ph.D., Chief Scientific Officer, Hec Pharma
Generic new drugs are being pushed to develop multiple Best-in-Class drugs to cover all patient population of all income levels in China and around the globe. The general approach as well as Hec Pharma's effort toward generic new drugs will be discussed.
PengCho Tang, Ph.D., Chief Scientific Officer, Hec Pharma
11:15
Innovative Drug R&D in China - A Possible Path
- Trend in Global and China Pharmaceutical Industry
- Possible Approaches for NCE Drug R&Din China
11:45
Drug Discovery in China, an IMPACT Perspective
The flagging productivity in the pharmaceutical R&D is largely due to disconnection between in vitro and in vivo evaluation of both drug-likeness and pharmacological properties; as well as disconnection between preclinical and clinical significance. The presentation will be focused on a new business model with successful cases.
Haijun Dong, Ph.D., President & CEO, IMPACT Therapeutics, Inc.
The flagging productivity in the pharmaceutical R&D is largely due to disconnection between in vitro and in vivo evaluation of both drug-likeness and pharmacological properties; as well as disconnection between preclinical and clinical significance. The presentation will be focused on a new business model with successful cases.
Haijun Dong, Ph.D., President & CEO, IMPACT Therapeutics, Inc.
12:15
Strategies for Drug Discovery and Development in China
To reduce risk and maximize return on investment, we have implemented a novel strategy that enables us to significantly abbreviate the timeline for drug discovery and development processes. Examples will be given to illustrate our model for drug development in China.
Xinqiang Li, Ph.D., President, Sunwei Therapeutics (Suzhou), Inc.
To reduce risk and maximize return on investment, we have implemented a novel strategy that enables us to significantly abbreviate the timeline for drug discovery and development processes. Examples will be given to illustrate our model for drug development in China.
Xinqiang Li, Ph.D., President, Sunwei Therapeutics (Suzhou), Inc.
12:45
Networking Luncheon with Exhibit & Poster Viewing
1:55
Chairperson's Remarks
Canwen Jiang, M.D., Ph.D., Vice President & Head of R&D Asia, Genzyme
Canwen Jiang, M.D., Ph.D., Vice President & Head of R&D Asia, Genzyme
2:00
Drug Discovery, Is China Ready?
Argusina is developing NCEs for type 2 diabetes and obesity. Harnessing drug discovery expertise from the US and the talent pool in China, we have developed a unique model to bring innovation to the global drug discovery arena.
Kanyin E. Zhang, Ph.D., Vice President and General Manager, Argusina (Shanghai) Ltd.
Argusina is developing NCEs for type 2 diabetes and obesity. Harnessing drug discovery expertise from the US and the talent pool in China, we have developed a unique model to bring innovation to the global drug discovery arena.
Kanyin E. Zhang, Ph.D., Vice President and General Manager, Argusina (Shanghai) Ltd.
2:25
Discussion on the New Drug R&D Circumstance and Pattern in China
This talk will present the effect of R&D circumstance and policy on drug innovation, how to create new drug development pattern in China in the coming "golden decade" of the 12th five-year plan, and the introduction of some successful cases.
Zhan Li, Ph.D., MBA, General Manager, Nanjing Changao Pharmaceutical Science & Technology Co., Ltd.; Executive Director, C&O Pharmaceutical Technology (Holdings) Limited; Chairman of the Board, Shanghai Sun-Sail Pharmaceutical Science & Technology Co., Limited
This talk will present the effect of R&D circumstance and policy on drug innovation, how to create new drug development pattern in China in the coming "golden decade" of the 12th five-year plan, and the introduction of some successful cases.
Zhan Li, Ph.D., MBA, General Manager, Nanjing Changao Pharmaceutical Science & Technology Co., Ltd.; Executive Director, C&O Pharmaceutical Technology (Holdings) Limited; Chairman of the Board, Shanghai Sun-Sail Pharmaceutical Science & Technology Co., Limited
2:50
Long Term Sustained Release Formulation of a Novel Dopamine Receptor Agonist A Potential Continuous Dopaminergic Simulation for the Treatment of Parkinson's Disease
In the de novo patient it is believed that providing a more continuous dopaminergic stimulation (CDS) from the start of antiparkinson therapy may prevent priming for motor fluctuations and dyskinesia. But there is no available formulation of CDS in the clinic application, except infusion, up to date. Long term sustained release system of the microspheres has the potential to offer CDS treatment of Parkinson's patients.
Youxin Li, Ph.D., Vice President, R&D, Luye Pharma Group Ltd.
In the de novo patient it is believed that providing a more continuous dopaminergic stimulation (CDS) from the start of antiparkinson therapy may prevent priming for motor fluctuations and dyskinesia. But there is no available formulation of CDS in the clinic application, except infusion, up to date. Long term sustained release system of the microspheres has the potential to offer CDS treatment of Parkinson's patients.
Youxin Li, Ph.D., Vice President, R&D, Luye Pharma Group Ltd.
3:15
Innovative Drug Discovery Efforts in TOT RD Center
TOT RD Center focuses on developing cancer gene therapy/immune therapy technology and products, especially developing new oncolytic virus products. In this talk, the efforts and rationale of current oncolytic virus projects in TOT RD Center will be discussed.
Min Liang, Ph.D., General Manager, TOT Shanghai RD Center Co., Ltd.
TOT RD Center focuses on developing cancer gene therapy/immune therapy technology and products, especially developing new oncolytic virus products. In this talk, the efforts and rationale of current oncolytic virus projects in TOT RD Center will be discussed.
Min Liang, Ph.D., General Manager, TOT Shanghai RD Center Co., Ltd.
3:40
Networking Refreshment Break with Exhibit & Poster Viewing
主题演讲 (3个会议的共通会议)
4:00
Chairperson's Remarks and Introduction of Keynotes
Tony Zhang, Ph.D., Vice President, Global External R&D, Asia, Eli Lilly & Co.
Tony Zhang, Ph.D., Vice President, Global External R&D, Asia, Eli Lilly & Co.
4:05
Key Factors to Be Successful in Emerging Markets
Ruiping Dong, M.D., Ph.D., Senior Vice President, Head of Emerging Markets R&D, Merck Research Laboratories
Ruiping Dong, M.D., Ph.D., Senior Vice President, Head of Emerging Markets R&D, Merck Research Laboratories
4:35
Innovation in Protein Therapeutics Research and Development
Clive R. Wood, Ph.D., Senior Vice President, Head of Global Biologics, Bayer Healthcare
Clive R. Wood, Ph.D., Senior Vice President, Head of Global Biologics, Bayer Healthcare
5:05
How to Introduce the Concept of "Change" in Biopharmaceuticals
Sam Waskal, Ph.D., Chairman & CEO, Kadmon Pharmaceuticals
Sam Waskal, Ph.D., Chairman & CEO, Kadmon Pharmaceuticals
5:35
Cocktail Reception in Exhibit & Poster Hall
2011年4月11日 (一) | 2011年4月12日 (二) | 2011年4月13日 (三)
总会: 中国的变革和技术革新
8:45
Chairperson's Opening Remarks and Introduction of Keynote Speaker
Xian-Ping Lu, Ph.D., CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.
Xian-Ping Lu, Ph.D., CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.
主题演讲
8:50
Innovation in China Chinese Government's Initiatives and Investment in the 12th 5-Year Plan
Hongguang Wang, Ph.D., Director General, China National Center for Biotech Development, Ministry of Science & Technology China
Hongguang Wang, Ph.D., Director General, China National Center for Biotech Development, Ministry of Science & Technology China
Panel Discussion
9:20
Dialogue Between the Stakeholders of Innovation in China Where Does Innovation Originate From? Locally or Globally?
Panelists:
Hongguang Wang, Ph.D., Director General, China National Center for Biotech Development, Ministry of Science & Technology China
Xian-Ping Lu, Ph.D., CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.
Frank Jiang, M.D., Ph.D., Vice President & Head, China R&D, Sanofi-Aventis
- Chinese government's innovation initiatives
- Chinese government's investment in biotechnology firms in 12th 5 year planning phase
- Role of MNCs in business growth/innovation in China
- How can MNCs and domestic companies bridge the gap and leverage on each other's expertise, funding and resources?
- How can MNCs assist in innovation initiatives by domestic companies?
Panelists:
Hongguang Wang, Ph.D., Director General, China National Center for Biotech Development, Ministry of Science & Technology China
Xian-Ping Lu, Ph.D., CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.
Frank Jiang, M.D., Ph.D., Vice President & Head, China R&D, Sanofi-Aventis
10:20
Networking Refreshment Break with Exhibit & Poster Viewing
Panel Discussion
10:50
Transformation & Innovation: Moving Up the Value Chain
Panelists:
Robert Armstrong, Ph.D., Vice President, Global External Research, Eli Lilly
Bin Li, Ph.D., Executive Director, Senior Equity Research Analyst, China Healthcare, Morgan Stanley
George Baeder, Senior Partner, Monitor Group
Li Chen, Ph.D., Chief Executive Officer, Hua Medicine
- What's the next stage for China's life sciences industry?
- What are the pros and cons of the different approaches of global pharma?
- How can China transform itself and expand from manufacturing and service to product and technology innovation?
- Lessons learned from other industries
- Global pharma R&D Productivity challenge and how China can help?
Panelists:
Robert Armstrong, Ph.D., Vice President, Global External Research, Eli Lilly
Bin Li, Ph.D., Executive Director, Senior Equity Research Analyst, China Healthcare, Morgan Stanley
George Baeder, Senior Partner, Monitor Group
Li Chen, Ph.D., Chief Executive Officer, Hua Medicine
Showcase: IBC-BayHelix Class of 2010
12:00
ASLAN Pharmaceuticals - An Asia-Enabled Pharmaceutical Company that Develops Novel Medicines for Global Markets
Carl Firth, Ph.D., MBA, Chief Executive Officer, ASLAN Pharmaceuticals
Carl Firth, Ph.D., MBA, Chief Executive Officer, ASLAN Pharmaceuticals
Hua Medicine An Innovator's Approach to Accelerated Development
John Choi, M.D., Ph.D., Co-Founder and Chief Strategy & Business Officer, Hua Medicine
Moderator: Li Chen, Ph.D., Chief Executive Officer, Hua Medicine
John Choi, M.D., Ph.D., Co-Founder and Chief Strategy & Business Officer, Hua Medicine
Moderator: Li Chen, Ph.D., Chief Executive Officer, Hua Medicine
12:30
Networking Luncheon in Exhibit & Poster Hall with Presentation of 2nd Annual IBC-BayHelix China Pharma R&D Awards
- China Scientific Discovery of the Year Award
- China Drug Discovery of the Year Award
- China R&D Award
创药到前临床开发、及合作
1:55
Chairperson's Opening Remarks
Stella Xu, Ph.D., Executive Director, Roche Partnering, Shanghai Roche (R&D) Center
Stella Xu, Ph.D., Executive Director, Roche Partnering, Shanghai Roche (R&D) Center
透过合作的价值创造
2:00
Drug Discovery R&D in China: Opportunities and Challenges
To fully capitalize on the initial investment and turn China into a RED (research and early development) hub for global MNCs, several hurdles need to be overcome, especially in the early clinical development area. This lecture will highlight these challenges and opportunities.
Mingqiang Zhang, Ph.D., FRSC, Chief Technology Officer and Vice President of External Innovation, Roche Research and Early Development, China
To fully capitalize on the initial investment and turn China into a RED (research and early development) hub for global MNCs, several hurdles need to be overcome, especially in the early clinical development area. This lecture will highlight these challenges and opportunities.
Mingqiang Zhang, Ph.D., FRSC, Chief Technology Officer and Vice President of External Innovation, Roche Research and Early Development, China
2:30
Simcere's R&D: International Collaboration as a Major Strategy
Abstract not available at time of print.
Peng Wang, Ph.D., Chief Scientific Officer, Simcere Pharmaceuticals
Abstract not available at time of print.
Peng Wang, Ph.D., Chief Scientific Officer, Simcere Pharmaceuticals
3:00
Sponsored Presentation Available
3:30
Networking Refreshment Break and Last Chance for Exhibit & Poster Viewing
4:00
Partnering for Success: an Overview of Pfizer's External R&D Innovation Strategy and Asia Initiatives
World leading pharmaceutical and biotech companies are attracted to China for a variety of partnership opportunities to leverage the country's strong basic research, talented scientific staff, and large patient pools. This talk will discuss biomedical R&D landscape in China, opportunities and challenges as well as Pfizer's strategy in building up R&D capability in China.
Yuan-Hua Ding, Ph.D., Senior Director & Head of External R&D Innovation Asia, Pfizer Inc
World leading pharmaceutical and biotech companies are attracted to China for a variety of partnership opportunities to leverage the country's strong basic research, talented scientific staff, and large patient pools. This talk will discuss biomedical R&D landscape in China, opportunities and challenges as well as Pfizer's strategy in building up R&D capability in China.
Yuan-Hua Ding, Ph.D., Senior Director & Head of External R&D Innovation Asia, Pfizer Inc
4:30
AstraZeneca's Approach to Drug Discovery & Development in China
The wave of MNCs setting up R&D centers in China is intensifying, although no two centers are same in strategy and operation model. Our experience in Shanghai for the last four years will be shared in pursuing parallel approaches with both in house research capabilities and external collaborations for new drug R&D.
Richard Wang, Ph. D., MBA, Director, Strategic Alliance Asia & Portfolio and Operation Management, Innovation Center China, AstraZeneca Global R&D
The wave of MNCs setting up R&D centers in China is intensifying, although no two centers are same in strategy and operation model. Our experience in Shanghai for the last four years will be shared in pursuing parallel approaches with both in house research capabilities and external collaborations for new drug R&D.
Richard Wang, Ph. D., MBA, Director, Strategic Alliance Asia & Portfolio and Operation Management, Innovation Center China, AstraZeneca Global R&D
5:00
Partnering a Chinese Local Company with a Licensing and Co-Development Model: Providing FDA Standard Clinical Data in China for NDA in Both FDA and SFDA.
To reduce the licensing fees and to take advantage of the low cost structure for R&D and the abundance of patient population in China, this presentation will introduce an efficient model that we have created, and which have made several successful deals. We will especially highlight a well-known case of in-licensing a FDA phase III potential blockbuster for stroke from Israel by partnering with a Chinese local company to provide FDA-standard clinical data in China for NDA in both FDA and SFDA.
Allan Riting Liu, M.D., Ph.D., M.B.A., Vice President, Wanbang Biopharmaceuticals; Director of Business Development, Fosun Pharmaceutical Group
To reduce the licensing fees and to take advantage of the low cost structure for R&D and the abundance of patient population in China, this presentation will introduce an efficient model that we have created, and which have made several successful deals. We will especially highlight a well-known case of in-licensing a FDA phase III potential blockbuster for stroke from Israel by partnering with a Chinese local company to provide FDA-standard clinical data in China for NDA in both FDA and SFDA.
Allan Riting Liu, M.D., Ph.D., M.B.A., Vice President, Wanbang Biopharmaceuticals; Director of Business Development, Fosun Pharmaceutical Group
5:30
Close of Day Two
2011年4月11日 (一) | 2011年4月12日 (二) | 2011年4月13日 (三)
8:50
Chairperson's Opening Remarks
Jing Shan (Jennifer) Hu, Ph.D., Director, Licensing & External Research, Merck & Company Inc.
Jing Shan (Jennifer) Hu, Ph.D., Director, Licensing & External Research, Merck & Company Inc.
毒性学和DMPK的课题
9:00
Benefits and Challenges of Conducting PreClinical Safety Study in China: Perspective from a Drug Development Company
The preclinical development in China has been established and rapidly progressed during last several years. Recently, the pharmaceutical companies and CROs continue to make solid progress in China and are moving into conducting late stage drug development studies, such as GLP toxicity study, to support the clinical trials and drug registration. This presentation will focus on illustrating the benefits and challenges of conducting preclinical toxicity study in China and discuss the strategies or solutions of overcoming some of these challenges based on the working experiences with different preclinical CROs.
James Yan, Ph.D., M.D., DABT, Executive Director, Head of Drug Safety Evaluation, Hutchison MediPharma Ltd.
The preclinical development in China has been established and rapidly progressed during last several years. Recently, the pharmaceutical companies and CROs continue to make solid progress in China and are moving into conducting late stage drug development studies, such as GLP toxicity study, to support the clinical trials and drug registration. This presentation will focus on illustrating the benefits and challenges of conducting preclinical toxicity study in China and discuss the strategies or solutions of overcoming some of these challenges based on the working experiences with different preclinical CROs.
James Yan, Ph.D., M.D., DABT, Executive Director, Head of Drug Safety Evaluation, Hutchison MediPharma Ltd.
9:30
Adventuring into Preclinical Development in China
GLP concept has been implemented in a fast pace in China. As one of the critical paths, pivotal preclinical data are expected to be generated from qualified CROs in China to support MNC's regional and global new drug submission. For small pharma, quality preclinical data are also highly valued to gain international acceptance. In today's Chinese preclinical arena, however, there are still lots of challenges to tackle such as the shortage of trained professionals, ICH guideline implementation, and acceptance with OECD MAD.
Yi Yang, M.D., Ph.D., Head of PreClinical Safety, China R&D, Director of Drug Safety Evaluation, sanofi-aventis China
GLP concept has been implemented in a fast pace in China. As one of the critical paths, pivotal preclinical data are expected to be generated from qualified CROs in China to support MNC's regional and global new drug submission. For small pharma, quality preclinical data are also highly valued to gain international acceptance. In today's Chinese preclinical arena, however, there are still lots of challenges to tackle such as the shortage of trained professionals, ICH guideline implementation, and acceptance with OECD MAD.
Yi Yang, M.D., Ph.D., Head of PreClinical Safety, China R&D, Director of Drug Safety Evaluation, sanofi-aventis China
10:00
Sponsored Presentation Available
10:30
Networking Refreshment Break
透过合作的价值创造 第二部
11:00
Challenges Of Selecting a Preclinical CRO for Your Multi-National IND Submissions
- What are the challenges
- What are the choices of Chinese CROs?
- Are these Chinese CROs GLP-compliant in terms of western standards?
- Should you outsource your preclinical studies to a Chinese CRO? If so, why. If not, why not.
11:30
Taiwan Biotech's Collaborations with China Companies
An overview of Taiwan's biotech industry will be presented. The content of the presentation includes: current status of biotech development in Taiwan, Taiwan's biotech policy & promotion status, Diamond action plan for biotech takeoff, recent accomplishments of Taiwan's biotech industry, and Taiwan biotech's collaborations with China companies.
Chia-Lin J. Wang, Ph.D., President, Development Center for Biotechnology, Taiwan
An overview of Taiwan's biotech industry will be presented. The content of the presentation includes: current status of biotech development in Taiwan, Taiwan's biotech policy & promotion status, Diamond action plan for biotech takeoff, recent accomplishments of Taiwan's biotech industry, and Taiwan biotech's collaborations with China companies.
Chia-Lin J. Wang, Ph.D., President, Development Center for Biotechnology, Taiwan
12:00
Innovative Strategies for Accessing External Innovation: GSK's Experience
Abstract not available at time of print.
Paul B. Bolno, M.D., MBA, Vice President, Worldwide Business Development, Head of Asia, GlaxoSmithKline
Abstract not available at time of print.
Paul B. Bolno, M.D., MBA, Vice President, Worldwide Business Development, Head of Asia, GlaxoSmithKline
12:30
Partnering with Eli Lilly
Eli Lilly and Company is a global pharmaceutical company with extensive capabilities and expertise in the development of small and large molecule. This presentation will discuss Lilly's evolving strategies in identifying outstanding partners around the globe to discover, develop and commercialize innovative medicines that improve patient outcomes.
Yetunde Taiwo, Ph.D., Senior Director, Global External R&D, Eli Lilly & Co.
Eli Lilly and Company is a global pharmaceutical company with extensive capabilities and expertise in the development of small and large molecule. This presentation will discuss Lilly's evolving strategies in identifying outstanding partners around the globe to discover, develop and commercialize innovative medicines that improve patient outcomes.
Yetunde Taiwo, Ph.D., Senior Director, Global External R&D, Eli Lilly & Co.
1:00
Close of Discovery to PreClinical Development & Partnerships
Copyright IBC Life Sciences, a part of Informa Life Sciences Group - 中文官方网站营运 : IBC Life Sciences 代理商 日商环球讯息有限公司